The Hidden Cost Running Through Every Oncology Trial

Run the numbers on any Phase III oncology trial and you'll find a hidden cost buried in the operations — not in the science. The average Phase III oncology trial runs at 15–25 sites. Tufts CSDD data shows roughly 40% of those trials miss their enrollment timelines. The reason isn't site-level execution. It's the coordination layer nobody budgets for.

15–25

sites per Phase III oncology trial (avg)

~40%

miss enrollment timelines (Tufts CSDD)

The Coordination Tax

There are four concrete costs that don't show up in any line item but compound into the difference between a trial that finishes on time and one that doesn't.

Duplicate Outreach

When two sites in the same network contact the same patient for overlapping trials. The patient gets confused. Gets frustrated. Opts out. A patient lost to poor coordination is gone — even if they were eligible for the right trial.

Capacity Blindness

Sites run at 130% while others sit idle 800 miles away. Sponsors don't know which sites are over-committed until enrollment stalls. By then, the window is closed.

Eligibility Cannibalization

Same patient pool gets targeted by two trials within the same sponsor's portfolio — trials that don't know about each other. Internal competition for the same patients drives up screen-fail rates and inflates cost-per-enroll.

Protocol Amendment Cascades

One amendment. Fifteen sites. Manual re-matching of hundreds of patients to updated criteria. Historically this meant printing charts and sitting in hallways for hours. The delay from one amendment can cost more enrollment time than the amendment itself.

The Math

A 15-site Phase II trial targeting 200 patients over 18 months. Each site runs roughly $40K/month in overhead, monitoring, and coordinator time. A 3-month delay at even half those sites = $900K in sunk costs before a single patient enrolls.

$1.8M Estimated cost of a 3-month delay on a 15-site, 200-patient Phase II trial

Scale it: a 20-site oncology program at $50K/site/month carries a $30M/year coordination risk that nobody is pricing in. The trial budget has a line for CRO fees, site management, and monitoring. Nobody puts a line on "coordination overhead." It lives in the gap between budget and reality.

Why Coordinators Can't Fix It

It's not willingness. A CRC running six sites across three concurrent trials with two protocol amendments per year is not going to solve this with a better spreadsheet. The problem is span-of-attention — too many moving parts, too many conflicts, too many patients who need re-scoring after every amendment.

Three trials. Ten sites. 400 patients. 40% overlap.

That's the scenario playing out in oncology programs across the industry right now. The coordination layer isn't a staffing problem — it's a data and sequencing problem. Without a system that sees the full portfolio and flags conflicts in real time, coordinators are working blind.

Run the scenario yourself →

You can run this scenario yourself.

Try the Multi-Site Demo →

If you're running multi-site oncology trials

I'd like to compare notes. We can map your portfolio against your site network and look at where the coordination gaps are — no pitch, just conversation. melinda@syncra.health